Summary The anti-tumour alkaloid taxol shows strong cytotoxic and antiproliferative activity in two human malignant glioma cell lines, T98G and LN-229. CD95 (Fas/APO-1) ligand is a novel cytotoxic cytokine of the tumour necrosis factor (TNF) family that exerts prominent antiglioma activity. At clinically relevant taxol concentrations of 5-100 nM, taxol and CD95 ligand showed significant synergistic cytotoxicity and growth inhibition. High concentrations of taxol induced G/M cell cycle arrest in both cell lines. The synergy of taxol and CD95 ligand was independent of cell cycle effects of taxol as synergy was achieved at much lower taxol concentrations than G/M arrest and as cell cycle effects of taxol were unaffected by co-exposure to CD95 ligand. Similarly, high concentrations of taxol were required to induce p53 activity in the p53 wild-type cell line LN-229. This effect was not modulated by CD95 ligand, suggesting that synergy is also independent of p53 activation. However, taxol induced a mobility shift of the bcl-2 protein on immunoblot analysis, indicative of bcl-2 phosphorylation. Bcl-2 phosphorylation on serine was confirmed by immunoprecipitation and phosphoserine immunoblot analysis. Considering (1) that phosphorylation of bcl-2 interferes with its heterodimerization with bax and (2) the inhibition of CD95-mediated apoptosis by bcl-2, we propose that taxol sensitizes malignant glioma cells to CD95 ligand by increasing the functional bax/bcl-2 rheostat in favour of bax and thus cell death.
The median survival of malignant glioma patients receiving cytoreductive surgery, radiotherapy and adjuvant chemotherapy does not exceed 1 year. There is thus an urgent need for new experimental approaches to effective forms of treatment and for the exploration of novel antineoplastic drugs.
Taxol is a plant-derived cytotoxic agent that has been proposed to act via a novel mechanism of action: prevention of tubulin depolymerization, stabilization of microtubules and promotion of tubulin polymerization (Schiff et al, 1979; Horwitz et al, 1986) . The p53 tumour suppressor gene product mediates growth arrest and DNA repair or apoptosis in response to genotoxic stimuli. Its major effects depend on the activation of target genes, such as p21, associated with growth arrest, and bax, linked to p53-mediated apoptosis. Actions of taxol documented in vitro include induction of G/M cell cycle arrest in human leukaemic cells (Horwitz et al, 1986; Rowinsky et al, 1988) , induction of p53 activity and expression of p21 (Blagosklonny et al, 1995) , and induction of apoptosis in breast cancer and myeloid leukaemia cells (Bhalla et al, 1993; Blagosklonny et al, 1996) . Selective disruption of p53 in otherwise genetically intact fibroblasts enhanced rather than decreased sensitivity to taxol (Wahl et al, 1996) . Taxol-mediated antineoplastic effects on various transplanted tumors in vivo correlate with taxolinduced apoptosis but not with mitotic cell cycle arrest after treatment with taxol (Milross et al, 1996) . More recently, it has been proposed that taxol may act to phosphorylate the bcl-2 protein and thereby attenuate bcl-2 affinity for the bax protein. Bax would mediate apoptosis when released from bcl-2 heterodimers (Blagosklonny et al, 1996; Haldar et al, 1996) .
TNF-ax, a pleiotropic cytokine mediating inflammatory and immunological reactions, has been demonstrated to act synergistically with taxol on ovarian carcinoma cells in vitro (Williams et al, 1992; Berkova and Page, 1995) . However, TNF-a also decreases TNF-a receptor density in macrophages (Ding et al, 1990) .
Taxol is used mainly for patients with platin-refractory ovarian cancer and breast cancer. Based on promising studies on the effects of taxol on cultured glioma cells Silbergeld et al, 1995) and glioma xenografts (Riondel et al, 1992) , several clinical studies of taxol for human malignant glioma patients have been conducted (Chamberlain and Kormanik, 1995; Glantz et al, 1995a ; Prados et al, 1996) . The disappointing results of these studies are probably partly due to the poor penetration of taxol into the brain at doses that are tolerated when given systemically (Glantz et al, 1995b) . Although taxol may penetrate pathological vessel walls within tumour tissue much more efficiently than intact brain vessel walls (Heimans et al, 1994) , it is clearly desirable to expose as many tumour cells to taxol as long as possibly achievable. Using local controlled delivery devices, such as taxol polymers, may be useful in circumventing this problem . This local application might also prove useful combined with post-operative radiotherapy as taxol is a radiosensitizer for glioma cells in vitro (Tishler et al, 1992) . We have been involved in the development of a novel approach to malignant glioma that is based on the targeted induction of apoptosis via activation of the CD95 cytokine receptor protein (Weller et al, 1994 (Weller et al, , 1995a Roth et al, 1997) . The present study was designed to examine possible synergistic interactions between taxol, TNF-a and CD95 ligand to design an efficient immunochemotherapy for malignant glioma. Further, we have examined possible links between synergy, CD95 expression, cell cycle effects and activation of p53, p21, bax and bcl-2.
MATERIALS AND METHODS Chemicals and cell lines
The human malignant glioma cell line LN-229 was kindly provided by Dr N de Tribolet (Lausanne, Switzerland). T98G human glioma cells were obtained from ATCC (Rockville, MD, USA). TNF-ax was purchased from Boehringer Mannheim (Germany). p53 antibody pAbl801 was from Oncogene Science (Uniondale, NY, USA), human bcl-2 antibody from Dakopatts (Glostrup, Denmark) and phosphoserine antibody from Sigma (St Louis, MO, USA). p21 and bax antibodies were obtained from Santacruz (Santacruz, CA, USA). Trypan blue was purchased from Biochrom KG (Berlin, Germany), taxol (paclitaxel) and propidium iodide were from Sigma. FITC-UB2 anti-Fas antibody was from Immunotech (Hamburg, Germany), FITC-mouse IgGl was from Sigma. The murine neuroblastoma cell line Neuro-2A was maintained in minimal essential medium (MEM) supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 1% non-essential amino acids and 1% penicillin/streptomycin. Neuro-2A cells engineered to produce soluble murine CD95 ligand have been described elsewhere (Rensing-Ehl et al, 1995) . One unit of cytotoxic activity attributable to CD95 ligand in Neuro-2A supernatants was defined as the activity required for half-maximal killing of the CD95 antibody-sensitive glioma cell line LN-18 (Weller et al, 1994) . The experiments using CD95 ligandcontaining supernatants were performed using supernatant from pooled neo vector control Neuro-2A cells as control.
Cell culture and detection of cytotoxicity and growth inhibition The human glioma cell lines were cultured in Dulbecco's modified Eagle medium (DMEM) containing 10% FCS, 1 mm glutamine and 1% penicillin/streptomycin as previously described (Weller et al, 1994 (Weller et al, , 1995b . Viability and proliferation were assessed by crystal violet staining or by trypan blue dye exclusion. For cytotoxicity assays, 5 x 103 glioma cells were plated in 96-well plates, adhered for 24 h, exposed to taxol or CD95 ligand or TNF-ax, or combinations thereof, for 72 h in complete medium. For growth inhibition assays, 1.5 x 103 glioma cells were plated in 96-well plates, adhered for 24 h, exposed to the respective agents, and allowed to recover for five generation times in fresh agent-free medium. Generation times were 24 h for LN-229 and 26 h for T98G.
Flow cytometry
For cell cycle analysis, the glioma cells were exposed to taxol or CD95 ligand or both for 24 h, washed, incubated with trypsin for 3 min at 37°C, harvested, washed and fixed with 70% ice-cold ethanol. Approximately 106 cells per condition were stained with propidium iodide (50 tg ml-' in phosphate-buffered saline (PBS), containing 100 tg ml RNAase A), washed and subjected to flow cytometric analysis of DNA content using a Becton Dickinson FACScalibur cytometer. Results are presented as histograms. The percentage of apoptotic cells after exposure to taxol or CD95 ligand or both was also assessed by FACS analysis. After treatment, the cells were harvested by trypsinization, washed with Dulbecco's PBS and fixed with ice-cold 70% ethanol. The dead cells of each sample, which had detached from the culture flask, were harvested from the supernatant by centrifugation and subjected to the same procedure as the non-detached (viable) cells. One day after fixation the cells were centrifuged, washed with Dulbecco's PBS and stained with propidium iodide. The percentage of the sub-G, fraction consisting of apoptotic nuclei was calculated by CellQuest software (Becton Dickinson, CA, USA).
Detection of CD95 expression
For flow cytometric analysis of CD95 expression, glioma cells were detached from the culture dishes, harvested into ice-cold complete medium containing 10% FCS, centrifuged and resuspended in FACS buffer (1% bovine serum albumin (BSA)/PBS/0.01% sodium azide). Subsequently, 10 p1 of FITC-UB2 anti-Fas antibody was added per sample (106 cells) or, as a control, FITC-mouse IgG,. After incubation and washing, samples were resuspended in 300 g1 of PBS containing 1% formaldehyde and stored light-protected at 40C before analysis by a Becton Dickinson FACScalibur cytometer. The specific fluorescence index (SFI) was calculated as the ratio of the mean fluorescence values obtained with the specific CD95 antibody and the isotype control antibody (Weller et al, 1995c) . For cytotoxicity assays, the glioma cells were exposed for 72 h to taxol or the cytokines and viability was determined by crystal violet staining immediately thereafter. For growth inhibition assays, the cells were exposed to the agents for 24 h, had their medium replaced by drug-free medium and were allowed to recover for five generation times before crystal violet staining (n = 3, mean ± s.d.)
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Immunoblot studies for the detection of p53, p2l, bcl-2 and bax protein expression were performed according to standard procedures as previously described (Weller et al, 1994) . Briefly, glioma cell cultures treated as indicated were rinsed with cold PBS and harvested into cold PBS containing phenylmethylsulphonyl fluoride (10 gg ml-') with a cell scraper. The cells were centrifuged and resuspended in lysis buffer (0.12 M sodium chloride, 0.01 M Tris HCI, 0.005 M EDTA, 0.5% Triton, 2 ,ug ml-' aprotinin, 100 gg mi-' phenylmethylsulphonyl fluoride) for 10 min on ice. The lysates were centrifuged for 10 min in a microfuge at 13 000 r.p.m. Soluble supernatant protein (20 jig per lane) was separated on 10% (p53) or 15% (p21, bax, bcl-2) polyacrylamide gels and blotted onto nitrocellulose by standard procedures. The membranes were washed, incubated with primary antibody (2 jig ml-'), washed, incubated with secondary antibody (alkaline phosphatase conjugate) and stained with nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate in 0.1 M Tris HCI containing 50 mm magnesium chloride and 10 mm sodium chloride.
Immunoprecipitation
Approximately 106 human glioma cells were washed with ice-cold PBS, harvested into PBS containing phenylmethylsulphonyl fluoride (10 jig ml-l) and lysed in lysis buffer for 10 min on ice (see above). Cell nuclei and debris were removed by centrifugation at 13 000 r.p.m. for 10 min. After pre-clearing the lysates with mouse IgG and protein G-Sepharose for 30 min and centrifugation, the lysates were incubated with bcl-2 antibodies overnight. Immunoprecipitates were then captured with protein G-Sepharose for 60 min. After washing the immunoprecipitates in lysis buffer, the samples were separated on a 15% polyacrylamide gel, blotted onto nitrocellulose, washed, incubated with biotinylated phosphoserine antibody and stained with nitroblue tetrazolium chloride and 5-bromo-4-chloro-3-indolyl phosphate in 0.1 M Tris HCI containing 50 mm magnesium chloride and 10 mm sodium chloride.
Analysis of synergy
Synergy was evaluated (1) by the fractional product method of Webb (1963) , which allows an evaluation of synergy at a defined level of effect, and (2) by the isobologram method (Berenbaum, 1981) , which reveals synergy over a broad range of concentrations.
In the fractional product method, the (additive) effect of two independently acting agents is defined as the product of the unaffected fractions after treatment with either agent alone: Figure 6 Bcl-2 phosphorylation on serine after exposure of glioma cells to taxol. LN-229 glioma cells were exposed to 50 nM taxol for 24 h (A, C) or untreated (B, D). As outlined in Materials and methods, bcl-2 was immunoprecipitated and the precipitates subsequently subjected to SDS-PAGE and immunoblot analysis for phosphoserine residues. As control, the lysates of treated (C) and untreated (D) cells were immunoprecipitated with mouse IgG isotype control antibody and subjected to the same immunoblot procedure as the bcl-2 immunoprecipitates (A, B) 1994). Using the natural CD95 ligand derived from CD95 ligandexpressing murine neuroblastoma cells (Rensing-Ehl et al, 1995) , efficient killing was achieved in the absence of such agents, LN-229 being more resistant to CD95-mediated apoptosis, as previously reported (Weller et al, 1994) . Exposure to high concentrations of CD95 ligand, e.g. 800 U ml-' induced prominent cytotoxicity within 24 h, i.e. 32% in LN-229 and 83% in T98G cells. Accordingly, lower concentrations of CD95 ligand were selected for the synergy studies.
As previously reported (Zuber et al, 1988 ) and confirmed in our previous studies (Weller et al, 1994) , relevant concentrations (<250 ng ml-') of TNF-a were neither cytotoxic nor growth inhibitory to human glioma cells in the absence of inhibitors of RNA and protein synthesis (Table 1) .
Synergistic cytotoxicity and growth inhibition after co-exposure to taxol and CD95 ligand Next, we asked whether cytotoxicity and growth inhibition induced by co-treatment with taxol and either CD95 ligand or TNF-a are synergistic, independent (additive) or antagonistic compared with the effects of exposure to either agent alone. The cells were treated with taxol or the cytokines, or their combination, either for 72 h or for 24 h with a recovery of five generation times.
According to the fractional product method, there was synergy between taxol and CD95 ligand both in the growth inhibition assay (Figure 1 ) and in the cytotoxicity assay (data not shown) for both cell lines. In contrast, there was no such effect with the combination of taxol and TNF-a. This approach assumes synergy if the observed effect of co-treatment significantly exceeds the predicted (additive) effect. Synergy of taxol and CD95 ligand was also demonstrated by isobologram analysis (Figure 2) . Here, the cells were exposed to broad concentration ranges of taxol, CD95 ligand or a combination of both for 72 h. Median effect concentrations were determined (EC50) and depicted graphically as isobolograms, as outlined in Materials and methods. The discrepancy between the predicted and the observed effect allows visualization of the synergy. Synergy according to isobologram analysis was also confirmed in the growth inhibition paradigm (data not shown).
Taxol does not enhance CD95 cell surface expression in human glioma cells One possible mechanism of synergy between CD95 ligand and taxol is drug-induced augmentation of CD95 expression in the glioma cells, which would result in enhanced CD95-dependent signalling. Therefore, we examined CD95 expression in LN-229 and T98G glioma cells by flow cytometry after exposure to increasing concentrations of taxol for 24 h. Table 2 provides SFI values for CD95 expression (see Materials and methods). A SFI of 1.0 indicates that there is no difference in binding of CD95 antibody compared with an isotype control antibody. Untreated LN-229 and T98G human glioma cells were CD95 positive (SFI > 1.0) as previously reported (Weller et al, 1995c) . Flow cytometry histograms revealed a rather homogeneous expression of CD95 (data not shown). This base line expression of CD95 was not enhanced by taxol. In fact, CD95 expression was unaffected in LN-229 cells and decreased rather than enhanced in T98G cells exposed to taxol.
Independence of synergy from taxol-induced cell cycle arrest To address the mechanism underlying synergy of taxol and CD95 ligand, we compared the effects of taxol (0, 50, 500 or 1000 nM) and taxol plus CD95 ligand (8 or 80 U ml-') on the cell cycle distribution of LN-229 and T98G cells. High concentrations of taxol (500 nM) induced a cell cycle block in G2/M phase, whereas lower nanomolar concentrations had no such effect (Figure 3) . In contrast, these lower concentrations were rather effective in inducing synergistic glioma cell killing and growth inhibition when co-administered with CD95 ligand (Figures 1, 2 and 4) . This was further confirmed by flow cytometry, which was used to detect apoptotic cells as the sub-G, fraction that encompasses apoptotic cell nuclei and larger cellular remnants. The sub-G fractions of T98G cells after a 24-h treatment with taxol only or CD95 ligand only were 1.5-fold or 1.7-fold higher than the sub-G, fraction of untreated control cells (Figure 4) . However, the sub-G, fraction of glioma cells co-exposed to taxol and CD95 ligand was 5.1-fold increased. Absolute percentages of the sub-GI fraction were 4.1% in untreated cells, 6.0% with 50 nM taxol, 7.1% with 8 U ml' CD95 ligand and 21.2% for 50 nM taxol plus 8 U ml' CD95 ligand. p53 and p53 target gene expression after exposure of human glioma cells to taxol and CD95 ligand: taxolinduced phosphorylation of the bcl-2 protein LN-229 has wild-type p53 activity, whereas T98G is mutant for p53 (Van Meir et al, 1994; Weller et al, 1997) . While the p53 wildtype cell line LN-229 was more resistant to taxol than the p53 mutant cell line T98G, this difference was not striking (Table 1) . We examined changes in p53 expression and expression of two p53 target genes, p21 and bax, after exposure to taxol and asked whether such changes were modulated during synergistic augmentation of taxol toxicity by CD95 ligand (Figure 5) mutations result in accumulation of p53 protein because of a prolonged half-life of the mutant protein, as is shown here for T98G. The p21 protein is thought to be responsible for p53-and drug-induced growth arrest in GJG1. Interestingly, there was no induction of p21 in either cell line, even though p53 was induced in LN-229 cells. Camptothecin (5 gM) was used as a positive control to illustrate that p21 can be induced in these glioma cell lines (p21 blots, right outer lanes). These data fit nicely with the flow cytometry findings, which clearly indicated a G2/M, but not GIG1, arrest after glioma cell exposure to taxol (Figure 3) .
Further, we assessed expression of the bax protein, a key mediator of p53-induced apoptosis as well as p53-independent cell death, which is antagonized by the prototype anti-apoptotic protein bcl-2. Again, there was no modulation of bax expression by either taxol alone or taxol plus CD95 ligand, suggesting that (1) taxol-induced p53 activity is insufficient for significant transcriptional effects on major target genes and that (2) enhanced bax expression mediates neither taxol-nor CD95 ligand-induced apoptosis. However, susceptibility to apoptosis may depend more on the relative expression levels of functional antagonists, such as bax and bcl-2 or bcl-x, than on their absolute levels. To inhibit the proapoptotic effects of bax homodimers, bcl-2 forms heterodimers with bax (Oltvai et al, 1993) . Recently, it has also been shown that taxol induces phosphorylation of bcl-2 and that phosphorylated bcl-2 fails to prevent apoptosis because of its inability to bind Bax (Haldar et al, 1995 (Haldar et al, , 1996 . In line with these data, we observed a mobility shift of the bcl-2 protein in glioma cells exposed to taxol (Figure 5 ), which is suggestive of phosphorylation (Haldar et al, 1995) . Immunoprecipitation of bcl-2 and subsequent immunoblot analysis of phosphoserine revealed that the observed change in mobility of bcl-2 was due to phosphorylation on serine ( Figure 6 ). In contrast to p53 activation and G2/M cell cycle arrest, bcl-2 phosphorylation was seen even with low concentrations of taxol (50 nM), which are sufficient for synergy with CD9S ligandinduced cytotoxicity. CD95 ligand administered alone had no such effect and did not modulate the effect of taxol on bcl-2 migration patterns upon co-treatment. In fact, even excessive, highly cytotoxic concentrations of CD95 ligand did not induce specific changes in the candidate regulatory proteins for apoptosis examined here (data not shown).
DISCUSSION
Human malignant glioma cells are rather resistant to multiple proapoptotic stimuli, including irradiation and most cytotoxic drugs. The mechanisms underlying this failure to respond to therapy may include loss of p53 and enhanced expression of antiapoptotic gene products, such as bcl-2, but are incompletely understood . We have previously reported that glioma cells are not resistant to apoptosis induced by agonistic antibodies that activate the CD95 cytokine receptor protein (Weller et al, 1994) . Moreover, we have noted that these cells are even more sensitive to apoptosis induced by the endogenous CD95 ligand, a cytokine homologous to TNF-a (Roth et al, 1997) . The main problem with CD95 ligand-based immunotherapy of malignant gliomas is probably prevention of systemic toxicity as agonistic antibodies to CD95 induce liver failure within a few hours when applied systemically (Ogasawara et al, 1993) . However, a local CD95-based approach to malignant glioma appears to be feasible.
Thus, growth of an intraperitoneal lymphoma can be controlled by intraperitoneal CD95 ligand applied locally (Rensing-Ehl et al, 1995) , and intra-articular application of CD95 antibodies can control arthritis (Fujisawa et al, 1996) , both in the absence of systemic toxicity. Further, circulation of CD95 ligand is not inevitably lethal (Sato et al, 1996) . As systemic toxicity depends on the dose of CD95 ligand applied and as maximal glioma cell killing is to be achieved, we have been particularly interested in immunochemotherapy based on co-treatment of glioma cells with CD95 ligand and cancer chemotherapeutic drugs (Roth et al, 1997) . The current focus is on taxol for several reasons: (1) taxol has previously been reported Silbergeld et al, 1995) and confirmed here to have strong anti-glioma effects in vitro; (2) taxol limits growth of glioma xenografts in mice (Riondel et al, 1992) ; and (3) taxol has already been adapted for local controlled release therapy of malignant gliomas and shown to be effective in a rat glioma model ).
The present study shows that the combination of taxol and CD95 ligand results in synergistic cytotoxicity and growth inhibition of human malignant glioma cells. Of note, no such effect is seen with TNF-a, a cytokine previously reported to cooperate with taxol in inducing cytotoxicity of ovarian carcinoma cells (Williams et al, 1992; Berkova and Page, 1995) . Synergy was not due to an enhanced expression of CD95 in taxol-treated glioma cells (Table 2) . Neither G2/M arrest nor induced expression of p53 or p21 was required for taxol toxicity of the glioma cells ( Figures  3 and 5) . Further, neither cell cycle effects nor constitutive or induced expression of these gene products appeared to be involved in the mechanisms underlying synergy of taxol and CD95 ligand, because synergy was obtained at concentrations of taxol that were insufficient to induce G2/M arrest or p53 expression. In contrast, positive interactions of taxol and irradiation appear to involve enhanced expression of p53 and p21 (Tishler and Lamppu, 1996) . The failure of taxol to induce p21 expression in the glioma cells examined here is consistent with a G2/M arrest as p21 is a mediator of G/G, arrest (Waldmann et al, 1995 ). Yet, taxol effects are probably cell type-specific as p21 was strongly induced in prostate and breast carcinoma cell lines (Blagosklonny et al, 1996) .
We confirm that taxol induces phosphorylation of bcl-2 (Haldar, 1995) . In contrast to p53 induction and G2/M cell cycle effects, the phosphorylation of bcl-2 protein was seen at low taxol concentrations that were sufficient to induce synergistic cytotoxicity of taxol and CD95 ligand. Phosphorylation of bcl-2 inhibits its heterodimerization with bax. Thus, although bax was not induced by taxol (Figure 5 ), the free levels of bax are likely to increase after taxol treatment because less bcl-2 is available for complex formation with bax (Blagosklonny et al, 1996; Haldar et al, 1996) . The fact that enhanced levels of free bax in LN-229 and T98G cells are associated with increased susceptibility to CD95 ligand is in perfect agreement with our previous observation that ectopic expression of bcl-2 in these cells attenuates the cytotoxic effects of agonistic CD95 antibodies (Weller et al, 1995b) and natural CD95 ligand (Roth et al, 1997) . CD95 ligand-based proapoptotic immunotherapy of malignant glioma is a promising novel option for the management of malignant gliomas (Weller et al, 1994 (Weller et al, , 1995a Immunochemotherapy of malignant glioma 411 taxol (Glantz et al, 1995b) . For reasons outlined above, both CD95 ligand and taxol are likely to be maximally effective when administered using a locoregionary approach. The present results call for an evaluation of local CD95 ligand plus taxol in an animal model of glioma.
